36 results about "Cyclic citrullinated peptide" patented technology

The invention discloses a test strip for detecting an anti-cyclic citrullinated peptide antibody by colloidal gold chromatography and a preparation method thereof. The test strip comprises a baseplate (7) and a nitrocellulose membrane (3), a conjugate pad (2), a sample pad (1) and a water-absorbing pad (6), which are sequentially stuck on the baseplate (7) by mutual lap joint. A detection region (4) and a quality control region (5) are arranged on the nitrocellulose membrane, the detection region is used for coating a cyclic citrullinated peptide antigen, the quality control region is used for coating the antibody which is used as a quality control material, and the conjugate pad is used for coating two different colloidal gold labeled antibodies. The test strip introduces the branch cyclic citrullinated peptide and carries out process improvement on pretreatment of the sample pad and the conjugate pad, and the invention provides the anti-cyclic citrullinated peptide antibody test strip with high sensitivity and strong specificity, which can quickly screen positive samples and further play an important role for early auxiliary diagnosis of RA and disease monitoring.

The present invention relates to method for assaying anti-cyclic citrullinated peptide antibodies in a clinical sample, said method comprising contacting said sample with at least one homogeneous reagent comprising at least one specific binder for anti- CCP antibodies, whereby to form a solution or suspension of an anti-CCP -binding partner complex in a homogeneous sample mixture and detecting the presence or level of said anti-CCP -binding partner complex in a homogeneous liquid-phase. The invention also relates to a method for the assessment of the existence of; risk of; potential for; or propensity to RA in a subject, said method comprising assaying for anti-CCP in a body sample from said subject in a homogeneous assay according to the invention, whereby to determine the level of anti-CCP antibodies in said sample, and correlating the thus-determined level with the existence of; risk of; potential for; or propensity to RA in said subject.

Use of a non-human mammalian disease model, wherein the non-human mammal has been implanted with human synovial tissue or other human inflamed tissue containing anti-CCP (cyclic citrullinated peptide) antibody producing cells for (i) analyzing cellular processes in a disease associated with anti-CCP antibodies in such human synovial tissue or other human inflamed tissue, (ii) studying the role of anti-CCP antibodies in the induction and progression of a disease associated with anti-CCP antibodies, (iii) testing the efficacy of a therapeutic agent for the prevention or treatment of a disease associated with anti-CCP antibodies, and (iv) identifying a therapeutic agent useful for the prevention or treatment of a disease associated with anti-CCP antibodies. In one embodiment the non-human mammalian disease model is a mouse, such as a SCID mouse, and the disease associated with anti-CCP antibodies is arthritis, such as RA (rheumatoid arthritis).

The invention discloses a kit for determining an anti-cyclic citrullinated peptide (Anti-CCP) antibody. The kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises a buffer solution, inorganic salt, surfactant, preservative, interference removing protein, modified CCP-sensitized nano poly styrene (PS) microspheres and ultrapure water; the reagent R2 comprises a buffer solution, inorganic salt, surfactant, preservative, an anti Anti-CCP second antibody and ultrapure water; and the weight ratio of the reagent R1 to the reagent R2 is (50-90):(10-50). According to the method, the Anti-CCP is determined by adding the anti Anti-CCP second antibody by a latex booster immunization transmission turbidimetry, a detection signal is subjected to two-stage amplification, the detection sensitivity is improved, and the determination range is enlarged; and the kit can be applied to an automatic biochemical analyzer to shorten detection time, and improve detection efficiency.

The present invention relates to method for assaying anti-cyclic citrullinated peptide antibodies in a clinical sample, said method comprising contacting said sample with at least one homogeneous reagent comprising at least one specific binder for anti-CCP antibodies, whereby to form a solution or suspension of an anti-CCP-binding partner complex in a homogeneous sample mixture and detecting the presence or level of said anti-CCP-binding partner complex in a homogeneous liquid-phase. The invention also relates to a method for the assessment of the existence of; risk of; potential for; or propensity to RA in a subject, said method comprising assaying for anti-CCP in a body sample from said subject in a homogeneous assay according to the invention, whereby to determine the level of anti-CCP antibodies in said sample, and correlating the thus-determined level with the existence of; risk of; potential for; or propensity to RA in said subject.

The invention discloses a three-in-one time-resolved fluorescence immunochromatography kit and a preparation method thereof. The three-in-one time-resolved fluorescence immunochromatography kit is composed of a PVC base plate, a glass fiber membrane, a conjugate pad, a nitrocellulose membrane and absorbent paper. A mouse anti-human IgG antibody marked by time-resolved fluorescent microspheres is contained in the combination pad; the nitrocellulose membrane comprises three detection lines: a T1 line is coated with cyclic citrullinated peptide recombinant protein; the T2 line is coated with n-pentamer protein 3 recombinant protein; the T3 line is coated with bispecific phosphatase 11 recombinant protein and a quality control C line; and the C line contains a goat anti-mouse IgG antibody. The kit can be used for rapidly and qualitatively detecting an anti-cyclic citrullinated peptide antibody or an anti-n-pentamer protein 3 antibody or an anti-bispecific phosphatase 11 antibody. The kit has the advantages of simplicity and convenience in operation, rapidness in reaction, high sensitivity and good specificity for early diagnosis of rheumatoid arthritis.

Rheumatoid arthritis is efficiently diagnosed with improved patient's convenience using a rheumatoid arthritis diagnosis composition and a kit, each including cyclic citrullinated peptide (CCP), a rheumatoid arthritis diagnosis method using the CCP, the rheumatoid arthritis diagnosis composition, or the kit, a method of obtaining information for rheumatoid arthritis diagnosis, and a method of screening a novel diagnostic marker for rheumatoid arthritis.

The invention relates to a composition for detecting immune antibodies of rheumatoid arthritis by a dot immunogold filtration assay, which comprises a cyclic citrullinated peptide (CCP) composition, a high molecular polymer, a microporous filtering film, a water absorption medium and a carrier medium, wherein the high molecular polymer is combined on the microporous filtering film in a covalent form or a non-covalent form; the CCP composition comprises CCP I and CCP II and is combined with the high molecular polymer in a covalent form or a non-covalent form; and the molar ratio of the CCP I to the CCP composition is 0-1. The composition not only can realize the purpose of quickly detecting the immune antibodies of rheumatoid arthritis in vitro but also is convenient for patients to carry out self-diagnosis, and provides a reference for knowing the progression of the disease in time.

The invention discloses a cyclic chimeric citrullinated peptide antigen and an application thereof. The preparation of the cyclic chimeric citrullinated peptide antigen comprises the following steps: firstly connecting and jogging three small-molecular antigen peptides, namely a citrullinated peptide1, a citrullinated peptide 2 and a citrullinated peptide 3 derived from a silk polymerizing protein / an intermediate filament protein, and then synthetizing a cyclic polypeptide with a similar protein beta-corner structure by forming a disulfide bond through two cysteines inserted into the end N and the end C of a chimeric peptide. The cyclic chimeric citrullinated peptide antigen coats a solid-phase vector to prepare an indirect enzyme linked immunosorbent assay kit used for detecting the hypotype of multiple anti-citrullinated protein antibodies contained in RA (Rheumatoid Arthritis) serum. The cyclic chimeric citrullinated peptide antigen and the ELISA kit thereof which are disclosed by the invention have the advantages of simple preparation and experimental operation process, good result repeatability, qualification or quantification and wide clinical application and scientific research value and are outstandingly enhanced in detection sensibility and diagnosis value on RA compared with an international similar kit.

The invention provides a citrulline modified peptide antigen combination and a composition comprising the citrulline modified peptide antigen combination. The invention also provides the use of the citrulline modified peptide antigen combination or the composition comprising the citrulline modified peptide antigen combination in preparation of a diagnostic tool detecting anti-citrulline modified peptide IgG antibodies and / or IgA antibodies. The citrulline modified peptide antigen combination provided by the invention is used for detecting IgG antibodies and / or IgA antibody markers, and solvesthe problem that 30% of clinical RA (rheumatoid arthritis) patients lack clear markers. The diagnostic tool provided by the invention adopts an antigen combination corresponding to the autoantibody ofa novel rheumatoid arthritis related biomarker to detect the autoantibody in human serum, has the advantages of good specificity, high sensitivity, good accuracy, wide linear range, safety, reliability and easy operation, and is especially suitable for screening and diagnosis of negative rheumatoid arthritis patients non-detectable by current clinical CCP2 (cyclic citrullinated peptide 2).

The invention provides a citrulline modified peptide antigen and a composition comprising the citrulline modified peptide antigen. The invention also provides the use of the citrulline modified peptide antigen or the composition comprising the citrulline modified peptide antigen in preparation of a diagnostic tool detecting anti-citrulline modified peptide IgG antibodies and / or IgA antibodies. Thecitrulline modified peptide antigen provided by the invention is used for detecting IgG antibodies and / or IgA antibody markers, and solves the problem that 30% of clinical RA (rheumatoid arthritis) patients lack clear markers. The diagnostic tool provided by the invention adopts an antigen corresponding to the autoantibody of a novel rheumatoid arthritis related biomarker to detect the autoantibody in human serum, has the advantages of good specificity, high sensitivity, good accuracy, wide linear range, safety, reliability and easy operation, and is especially suitable for screening and diagnosis of negative rheumatoid arthritis patients non-detectable by current clinical CCP2 (cyclic citrullinated peptide 2).

The invention discloses a kit for detecting a cyclic citrullinated peptide (CCP) and immunoglobulin G (IgG) resistant bispecific antibody, which belongs to the field of clinical laboratory science. The kit of the invention is developed based on an enzyme-linked immunosorbent assay technology, utilizes a double-antigen sandwich method, comprises two antigens of CCP and IgG and can detect a naturalbispecific antibody existing in the serum of a rheumatoid arthritis patient, is convenient for use and can simply and easily detect the bispecific antibody.